AOD-9604 benefits

Lists of AOD-9604 benefits read like a drug label. Trace each line back and you find mouse studies, one conference abstract, one dish of cancer cells, and a 24-week human trial that failed.

What AOD-9604 is claimed to do, and where each claim comes from

AOD-9604 is the tail end of human growth hormone, residues 176 to 191. It was built in the 1990s to keep the fat-burning signal and drop the rest of the hormone. That design story is why the benefit list exists.

Here is the list, with the source for each line.

One row has a controlled human trial behind it. That trial was negative. We cover it in full on the AOD-9604 before and after page.

Does AOD-9604 actually burn fat?

In mice, yes. In people, the best trial says no.

Heffernan and colleagues published metabolic studies of the synthetic lipolytic domain in Hormone Research in 2000. Ng and colleagues followed in Endocrinology in 2001, treating obese mice and beta-3 adrenergic receptor knockout mice over a longer course. Both reported effects on fat metabolism. That rodent work is real, and it is the reason the compound was developed.

The human arc started well too. A 2005 trade report in Inpharma Weekly carried this headline.

Note the word “may,” and note the route. That was oral dosing. Then came the big one: a 24-week placebo-controlled Phase IIb trial, 502 participants in the published account, with diet and exercise added to both arms. The compound stopped separating from placebo. Development ended.

Is there evidence AOD-9604 is not what made the fat move?

There is a paper worth knowing about, and its title is the finding.

That study used purified growth hormone, not AOD-9604. But it tests the premise the whole compound rests on. If purified hormone shows no direct lipolytic action on fat cells in culture, then the idea of isolating a “lipolytic domain” from it gets harder to defend.

It is one in vitro paper. It does not settle anything on its own. It does sit awkwardly next to a benefit list written as if the mechanism were closed.

Does AOD-9604 help joints, cartilage or bone?

There is no published controlled human trial of AOD-9604 for any joint or cartilage outcome. The count is zero.

The citation people reach for is Brennan, Rizzoli and Ammann, printed in a Bone supplement in 2009. Its title is a question.

• It is an abstract. Page S326 of a supplement is a conference listing, not a peer-reviewed full paper.
• It is about bone. Cartilage repair and knee pain are different outcomes and were not measured.
• It is preclinical. No human joint study of this compound has been published since.

Mendias and Awan reviewed approved and unapproved peptide therapies for musculoskeletal injury and athletic performance in Sports Medicine in 2026. AOD-9604 belongs in the unapproved column of that discussion. It has no regulatory approval for any injury indication anywhere.

Does AOD-9604 avoid growth hormone side effects?

That claim is a design goal that got rewritten as a result.

The fragment was cut from growth hormone specifically to leave behind the growth-promoting and insulin-antagonizing parts of the molecule. Heffernan’s 2000 metabolic work in Hormone Research was built around that question. The claim traces to that rationale and to rodent data.

What does not exist is a long human safety program. The published human record is six trials: two intravenous, at 25 to 400 µg/kg, and four oral, from 54 mg a day down to 0.25 mg. We found no published trial using injection under the skin, which is how the research market sells it. The dosage page lists what each trial administered.

“Fewer side effects than growth hormone” and “studied for safety the way an approved drug is” are not the same sentence. Only the first one has support, and it is indirect.

Does the GRAS label mean AOD-9604 is FDA approved?

No. GRAS stands for Generally Recognized as Safe. It is an FDA category for substances added to food. It is not a drug approval, and it says nothing about injecting anything.

There is also a sport issue. The World Anti-Doping Agency’s Prohibited List covers growth hormone fragments, and AOD-9604 is named in that section. Any tested athlete should treat it as banned. Our legality page covers the research-chemical framing.

What about the breast cancer cell study?

Habibullah and colleagues published in Drug Design, Development and Therapy in 2022. They loaded doxorubicin into chitosan nanoparticles and reported that the hGH fragment 176–191 enhanced toxicity against MCF-7 breast cancer cells.

That is cells in a dish, paired with a chemotherapy drug, in a drug-delivery experiment. It is not a cancer treatment finding. It is not a human finding. It does not belong in a benefit list, and when it shows up in one, it has been moved a long way from what was measured.

What a buyer can check instead

None of the benefit claims can be verified by you. Three other things can.

• Identity and purity. Ask for a batch-matched certificate of analysis with mass spec and HPLC. How to read one.
• Handling. Lyophilized peptide has real storage requirements. See storage temperature.
• Price sanity. Vials commonly run $30–$60 per 5 mg. Price tells you about the seller, not the molecule.

For scale on the fat-loss question, here is what compounds with positive Phase III data reported.

Those are trial results, reported here only for scale. The complete guide has the full development history.

Frequently asked questions